Asterias Biotherapeutics (AST) Misses Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. CPAY
8. DDOG
9. CHYM
10. PAYC

Go back to Asterias Biotherapeutics (AST) Misses Q3 EPS by 7c

Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study

November 14, 2016 4:01 PM EST

FREMONT, Calif., Nov. 14, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial results for the third quarter ended September 30, 2016.  In addition, the Company disclosed that there has been a recent acceleration in AST-OPC1 SCiStar study enrollment with three patients having been dosed over the past week. In addition to the previously completed dosing of the 2 million and 10 million cell AIS-A cohorts, Asterias has now treated two AIS-A patients with the maximum dose of 20 million AST-OPC1 cells and two AIS-B patients with 10... More